Uncle Sam Hands Cancer-Killing Cells to Maryland Firm
Published Date: 9/15/2026
Notice
Summary
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patents and patent applications listed in the Supplementary Information section of this notice to MedGene Therapeutics, Inc. ("MedGene"), a company located in Silver Spring, Maryland, the United States of America.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
Exclusive NIH License for HPV‑16 T‑cell Therapy
If you are a patient with an HPV‑16 E6–positive cervical, head and neck (including oropharyngeal), or anogenital cancer and you express HLA‑A*02, the National Cancer Institute is contemplating granting MedGene Therapeutics an exclusive, royalty-bearing patent license to develop and commercialize ex vivo engineered T‑cell therapies (autologous or allogeneic) that use T‑cell receptors reactive to the HPV‑16 E6 oncoprotein. The contemplated exclusive territory may include the United States, Japan, and the Republic of Korea, and written comments or license applications must be received by the NCI Technology Transfer Center on or before September 30, 2026 (notice published September 15, 2026).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-18646, Draft NIH Biosafety Policy for Research Involving Biohazards
The NIH is updating its biosafety rules to keep research safe as science changes and grows. This new policy will replace old guidelines and affect anyone working with biohazards in NIH-funded research. They want your thoughts by October 19, 2026, to help shape these important safety updates without adding extra costs.
2026-18191, Submission for OMB Review; 30-Day Comment Request Data and Specimen Hub (DASH) (Eunice Kennedy Shriver National Institute of Child Health and Human Development)
The National Institutes of Health (NIH) is asking for public feedback on their Data and Specimen Hub (DASH), which helps researchers share important health data. This is a quick 30-day review to make sure the information collection is clear and useful. If you’re involved in health research or data sharing, your input by October 8, 2026, can help shape how DASH works without costing extra money or time.
2026-17899, Proposed Collection; 60-Day Comment Request; Assurance (Interinstitutional, Foreign, and Domestic) and Annual Report (Office of the Director)
The NIH wants your thoughts on their plan to keep track of animal research safety through yearly reports and assurances from institutions, both in the U.S. and abroad. This helps make sure labs follow the rules and protect animals, with no new costs or big changes expected. You’ve got until October 2, 2026, to share your feedback and help improve the process!
2026-17687, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in October 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, ensuring fair and confidential decisions. Scientists applying for grants in genetics, molecular sciences, oral health, and cancer research are the ones affected, with no direct cost changes announced.
2026-17438, Center For Scientific Review; Notice of Closed Meetings
The NIH's Center for Scientific Review is holding several closed virtual meetings in late September 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers applying for funding. No direct money changes are announced, but these reviews decide who gets research grants.
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
Previous / Next Documents
Previous: 2026-18876, Notice of OFAC Sanctions Action
The U.S. Department of the Treasury's Office of Foreign Assets Control (OFAC) is publishing the names of one or more persons that have been placed on OFAC's Specially Designated Nationals and Blocked Persons List (SDN List) based on OFAC's determination that one or more applicable legal criteria were satisfied. All property and interests in property subject to U.S. jurisdiction of these persons are blocked, and U.S. persons are generally prohibited from engaging in transactions with them.
Next: 2026-18878, In the Matter of The Nasdaq Stock Market LLC; Order Granting Petitions for Review and Scheduling Filing of Statements Regarding an Order Approving a Proposed Rule Change, as Modified by Amendment No. 1, To Adopt a New Continued Listing Requirement